Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

This study has been terminated.
(study was stopped due to low accrual)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00924001
First received: June 17, 2009
Last updated: October 18, 2012
Last verified: October 2012
Results First Received: December 22, 2011  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Melanoma
Malignant Melanoma
Melanoma, Experimental
Interventions: Drug: DMF5 Melanoma Reactive TIL
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
One participant was enrolled to this study.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Metastatic Melanoma Melanoma that has invaded deep into the skin, lymph nodes, or other parts of the body.

Participant Flow:   Overall Study
    Metastatic Melanoma  
STARTED     1  
COMPLETED     1  
NOT COMPLETED     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Metastatic Melanoma Melanoma that has invaded deep into the skin, lymph nodes, or other parts of the body.

Baseline Measures
    Metastatic Melanoma  
Number of Participants  
[units: participants]
  1  
Age  
[units: participants]
 
<=18 years     0  
Between 18 and 65 years     1  
>=65 years     0  
Age  
[units: years]
Mean ± Standard Deviation
  32.0  
Gender  
[units: participants]
 
Female     0  
Male     1  
Ethnicity (NIH/OMB)  
[units: Participants]
 
Hispanic or Latino     0  
Not Hispanic or Latino     1  
Unknown or Not Reported     0  
Race (NIH/OMB)  
[units: Participants]
 
American Indian or Alaska Native     0  
Asian     0  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     0  
White     1  
More than one race     0  
Unknown or Not Reported     0  
Region of Enrollment  
[units: participants]
 
United States     1  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With an Objective Clinical Tumor Regression Response According to RECIST Criteria   [ Time Frame: 44 days ]

2.  Primary:   Number of Participants With Adverse Events   [ Time Frame: 44 days ]

3.  Secondary:   Number of Participiants With In-vivo Survival of Infused Cells   [ Time Frame: 44 days ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Steven Rosenberg
Organization: National Cancer Institute, National Institutes of Health
phone: 301-496-4164
e-mail: sar@mail.nih.gov


Publications:

Responsible Party: Steven A. Rosenberg, M.D./National Cancer Institute, National Institutes of Health
ClinicalTrials.gov Identifier: NCT00924001     History of Changes
Obsolete Identifiers: NCT00537069
Other Study ID Numbers: 070210, 07-C-0210
Study First Received: June 17, 2009
Results First Received: December 22, 2011
Last Updated: October 18, 2012
Health Authority: United States: Federal Government
United States: Food and Drug Administration